The Dutch health technology assessment institute, ZIN, has called for a debate on how society should tackle obesity and whether expensive treatments should be part of the national prevention strategy.
The health technology assessment (HTA) body for the Netherlands, ZIN, has declined to recommend Novo Nordisk’s obesity drug Wegovy (semaglutide) for reimbursement. The institute said there were unanswered questions about the drug’s effects and pointed to the global shortage of semaglutide as an additional consideration.
Novo Nordisk told the Pink Sheet it was disappointed by the decision but that it would welcome further dialogue with...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
